Key Highlights
- Biogen will acquire Apellis Pharmaceuticals in an all-cash transaction valued at roughly $5.6 billion.
- The offer price of $41 per share represents approximately a 140% premium over APLS’s prior closing price.
- Additional contingent value rights could deliver up to $4 per share based on Syfovre achieving specific sales targets.
- The acquisition brings Empaveli and Syfovre into Biogen’s portfolio, drugs that collectively delivered $689 million in revenue during 2025.
- Transaction completion is anticipated during Q2 2026.
Shares of Apellis Pharmaceuticals (APLS) skyrocketed more than 136% during Tuesday’s pre-market session on March 31, following the announcement that Biogen (BIIB) had reached a definitive agreement to purchase the specialty pharmaceutical company for approximately $5.6 billion. In contrast, Biogen’s shares declined nearly 7% on the announcement.
Apellis Pharmaceuticals, Inc., APLS
The $41 cash payment per share that Biogen is offering translates to roughly a 140% markup from APLS’s previous trading session close.
This transaction aligns with Biogen’s broader strategic initiative to diversify beyond its aging multiple sclerosis franchise by strengthening its presence in the immunology and rare disease sectors.
Apellis contributes two commercially available therapeutics to Biogen’s pipeline. Empaveli has received approval for treating two uncommon kidney conditions plus a rare blood disorder. Syfovre addresses geographic atrophy in its advanced stages, a major contributor to vision loss globally.
In 2025, these two medications generated combined sales of roughly $689 million. Both companies anticipate this revenue stream will expand at a mid-to-high teens compound annual growth rate through 2028 at minimum.
Additional Milestone-Based Compensation
On top of the $41 baseline acquisition price, Apellis shareholders stand to collect two separate conditional payments worth $2 apiece — potentially adding $4 per share — if Syfovre hits predetermined worldwide sales benchmarks.
This structure could push the total consideration to $45 per share under optimal circumstances.
Christopher Viehbacher, Biogen’s Chief Executive Officer, characterized the deal as aligned with the company’s strategic evolution. “The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio,” he said.
Subject to customary regulatory clearances and shareholder consent, the parties expect to finalize the transaction in the second quarter of 2026.
Acquirer’s Stock Feels the Pressure
While Apellis shareholders celebrated substantial gains, Biogen investors watched their stock retreat approximately 7% in pre-market activity following the disclosure.
Such negative market reactions are common when an acquiring company commits to a significant premium. Multi-billion dollar cash acquisitions frequently create near-term downward pressure on the purchaser’s equity, especially at this scale.
On TipRanks, BIIB carries a Moderate Buy consensus rating based on 11 Buy, 15 Hold, and 1 Sell analyst ratings. The consensus price target sits at $206.70, implying around 10% upside from recent levels, with the highest target at $250.
This purchase represents Biogen’s continued effort to pivot from its traditional MS product line toward faster-growing opportunities in rare disease therapeutics.
Based on the premium offered, Apellis shares were trading around $17 before the buyout announcement became public.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
